5 Insightful Analyst Questions From Collegium Pharmaceutical's Q1 Earnings Call
Collegium Pharmaceutical's first quarter results were well received by the market, with management crediting growth in its ADHD medicine Jornay and stability in its pain portfolio as the primary drivers. CEO Vikram Karnani highlighted that Jornay prescriptions grew 24% year-over-year, and all three pain medicines delivered single-digit revenue growth, despite typical first-quarter headwinds. Karnani emphasized, 'We have made significant progress on each of our strategic priorities,' citing the successful expansion of the sales force and continued investment in product differentiation as key factors supporting performance.
Is now the time to buy COLL? Find out in our full research report (it's free).
Revenue: $177.8 million vs analyst estimates of $172.8 million (22.7% year-on-year growth, 2.9% beat)
Adjusted EPS: $1.49 vs analyst estimates of $1.45 (2.8% beat)
Adjusted EBITDA: $95.15 million vs analyst estimates of $96.5 million (53.5% margin, 1.4% miss)
The company reconfirmed its revenue guidance for the full year of $742.5 million at the midpoint
EBITDA guidance for the full year is $442.5 million at the midpoint, above analyst estimates of $438.5 million
Operating Margin: 12.2%, down from 34.1% in the same quarter last year
Market Capitalization: $962 million
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Les Sulewski (Truist Securities) asked about Jornay prescription seasonality and the sales force expansion's geographic and frequency impact. Chief Commercial Officer Scott Dreyer explained that expanded reach and more frequent engagements are expected to show results later in 2025.
Les Sulewski (Truist Securities) questioned the potential for Jornay's delayed release technology to be applied to other compounds. CEO Vikram Karnani replied that previous attempts focused on methylphenidate, and current efforts are centered on maximizing Jornay's growth potential.
Les Sulewski (Truist Securities) inquired about the appetite for business development in the current environment. Karnani emphasized a disciplined approach, with capital deployment decisions guided by long-term shareholder value.
Serge Belanger (Needham & Co.) asked about ADHD market growth, prescriber base composition, and sources of Jornay's market share gains. Dreyer noted the market is growing 5-6% annually, with share gains driven mainly by switches from generic immediate-release products.
David Amsellem (Piper Sandler) asked about optimal sales force size for Jornay and peak sales expectations. Dreyer described the current sales force as 'right-sized' and Karnani said peak sales estimates would follow a full assessment of sales expansion impact.
In the coming quarters, the StockStory team will be monitoring (1) prescription growth trends for Jornay, especially following the expanded sales force and back-to-school campaigns, (2) stability and cash flow generation from the pain portfolio amid market headwinds and product exclusivity timelines, and (3) any updates on portfolio expansion or business development transactions. The company's ability to manage expenses after recent investments will also be a key area of focus.
Collegium Pharmaceutical currently trades at $29.93, up from $27.28 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it's free).
Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
28 minutes ago
- CBS News
This Sacramento County school district revives career training programs for students
More than 400,000 California students graduate from high school each year, and 62% will go on to college. Over the decades, many schools have phased out classes like auto shop and home economics in favor of college prep courses. But one local district is bringing back career training classes so students can get jobs without getting a four-year degree. Today's high school students in the Folsom Cordova Unified School District are learning a lot more than just the 3Rs. "The idea is that our students are not only ready for college, they're ready for careers," said Shanan Spears with the district. They're learning everything from hospitality positions like catering and being a chef to construction and manufacturing jobs like metal welding and woodworking. "It's going to help me in the long run, with not only securing a job, but if I'm at home and something breaks, I'm going to have the technical know-how to fix it," said Folsom High senior Dustin Davis. Software design, health care, and sales are some of the other career training that is offered. The district says these types of classes and internships give students skills that can lead to high-paying careers without the time commitment and cost of having to attend a four-year college. "They go to college because they think they're supposed to go to college, and they come out with a degree and they don't know what to do with it," Spears said. "They don't know where to go." School officials say there's a huge need for workers with these types of skills. "We almost don't even have enough students," Spears said. "There is a high demand, and we hope we're filling that gap just a little bit." Whether they go on to college, trade school, or get a job right after graduation, these students are getting professional experience before they even get a diploma. "I know each student has learned so much, including myself, and I'm so grateful to have this opportunity," said Varshini Nagam, a senior at Vista Del Lago High School. Around 26% of students in the Folsom Cordova district participate in these career classes, and the district says much of the funding for this training comes from state grants.
Bloomberg
28 minutes ago
- Bloomberg
'Taking From The Poor Giving to the Rich:' Sarin on Tax Bill
Natasha Sarin, President & Co-Founder of the Budget Lab at Yale University, talks about how the current Tax Bill will benefit the wealthy, add to the US deficit, and states that over the long run the tax cuts from this legislation will slow the economy. Sarin speaks with Kailey Leinz on the late edition of Bloomberg's 'Balance of Power.' (Source: Bloomberg)
Bloomberg
28 minutes ago
- Bloomberg
KIC's Park Says Treasuries Remain Core Portfolio
CC-Transcript 00:00One of the big questions that's come up this year was, you know, the role of US treasuries and whether or not, you know, people have overinvested or overallocated into Treasuries as the sovereign wealth fund. I know you guys have exposure to U.S. Treasuries. How are you looking at your holdings right now? And are you happy with your exposure to U.S. Treasuries? In the country, though, we are happy to invest, with an investment in the U.S. Treasury in a sense that the U.S. Treasury bond keeps are very strong, that liquidity and stable returns. And also, regardless of any sort of market volatilities, we are expecting a stable and the solid returns in the short term. So for the time being, we maintain our portfolio, the Treasury bond, as are our two core portfolios. But in the longer term we are mindful of any risks from the supply, supply change from the investors and also to the... Some are on policy uncertainties long term. Do you need to be rethinking that? How are you looking at your exposure to U.S. Treasuries longer term and how are you looking at potential alternatives to U.S. treasuries? Are there alternatives? We are now reconsidering our asset allocation. We understand that our long term returns are largely depend on our asset allocation. So among the total fixed income investments, we are also interested in investing to the credit and credit bond and other other to the structural bonds, along with the U.S. Treasury. And also more fundamentally, we are now considering to our asset allocation between the fixed income to the global equity. Do you see alternatives to public fixed income and would you be increasing you're looking to increase your weighting into things like private credit, for example, in private private lending? And is that what role do you see that part playing in your portfolio? That's a little bit. I'll start with the... The investment in fixed income. Now the we diversify our portfolio to alternative investments, including, as you said, private equity, the private credit and the infrastructure. So the more we believe the alternative investment, it will be our core assets in our portfolio in the longer term. So we are we plan to invest continuously, fairly and steadily pace the philosophy behind alternatives or going into, say, private credit, for example, is that is that because of returns or is that because of predictability and stability? What role why are you doing that? Well, always to the edge to support investment. Our key objective is the diversification of the asset. So the higher return is also very the is our top priority. But at the same time, the stability is is our one of the key objective is to manage our portfolio. So we understand alternative investment is very goal upon a long term investment. So we expect more reasonable risk return profile compared to the traditional investment, public investment. So among the alternative assets or we are trying to diversify our portfolios, as you mentioned, the private credit is is to the growing industry and also to we we are interested in investment in infrastructure where you already have a New York office, just a cloud that's been in for 15 years. But you have plans to is it to branch out a specific part of the fund that looks at us out of New York? What's what are you looking to do specifically there and why? Strengthening the function and the role of the overseas offices is these are all key objectives. Do you have a timeline of when you plan to do that? And do you have an initial. Amount in mind that you're looking to invest specifically there in in alternatives? The U.S. is already our largest the place for our alternative investment. And later this year, we are trying to establish a new dedicated pond which will the how big is it fund is we we are starting from the very small side and at the same time it's relative for us sovereign wealth fund if you can give guidance but but what's smallest. Yeah. Is is a smaller size it's it's compared to our to the typical investment in our country, investment to the size is very small but we want identify the very good investment opportunities in all states. So that's why we establish that this dedicate pond in New York and then we are doubling the performance of this operation, and then we can expand both inside and also in other details such where is it? Is it accurate to say that see is going overweight on the US as far as private markets go? And if that is accurate, tell us tell us why and how and do you do you have any concerns about your exposure to the US dollar, for example? Our exposure to U.S. is a heavy, but compared to other investors, I think our exposure to U.S. is at the reasonable level at this moment and also to hedge our longer term is investor rather than responding to just short term the volatility. We are trying to focus on that more long term growth potential and the structural trend that says we expect U.S. market trends continue, especially in tech sector. So hopefully we can see more opportunities. You mentioned China and some of the I guess some of the opportunities that you are looking at there. I know you have some exposure there as well. Could you elaborate more on that? Like what what future opportunities do you see in in China, whether it is public or private markets? And what would it take for you to then, I guess, establish an office to your point, by to then increase your on the ground capabilities? Yeah. In terms of Chinese market, it's a little bit tricky and it's complicated to invest in Chinese market. Is that an economic consideration and a geopolitical comparison force? And the Chinese tech sector is very promising. At the same time, Chinese private property market and macro condition is a little bit unclear. Also, I just say that in the political point of view, no, we see the the rivalry and the tension between the U.S. and China. So we have to concede at this point and we expect this trend to will be continuing for the time being. So now we are also seeing some fundamental change over world economic order. So now from the globalization tool, where we have more protectionism and supply chain disruption. So every countries are trying to protect their industries. Key industries, including air and high tech, is one of them.
